ArticleJournal of veterinary science2025
Evaluation of formulation and immunogenicity of porcine circovirus type 2d (PCV2d) vaccine for needle-free intradermal route injection.
Article in Journal of veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Article
- Emerging Challenges and Advances in Porcine Circovirus: A Decade in Review.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
importancePorcine circovirus type 2 (PCV2) is a major pathogen responsible for the porcine circovirus-associated disease, causing significant economic losses in the swine industry worldwide. PCV2d has become the dominant, following a sequential shift from the previously predominant PCV2a and PCV2b genotypes. Although an effective vaccine based on virus-like particles (VLPs) of recombinant PCV2d-based capsid protein has been developed, intramuscular inoculation of the vaccine still induces a wide variety of side effects. In contrast, intradermal vaccination offers benefits, including enhanced immune activation due to the abundance of dendritic cells in the dermal layer, while also reducing side effects.
objectiveDeveloping a novel vaccine combined with a needle-free inoculation technique is required to elicit protection against PCV2d infection with fewer side effects and higher effectiveness. This study aimed to develop a VLP-based vaccine targeting PCV2d and assess its efficacy when administered intradermally using a needle-free system.
methodsTo optimize the intradermal vaccine formulation, we evaluated humoral immunity and neutralizing activity following intradermal administration of test vaccines prepared with varying adjuvant types, adjuvant ratios, and antigen doses.
resultsIMS1313 adjuvant provided the best induction of total IgG and neutralizing antibody titers. A dose-dependent evaluation indicated that 20 μg of antigen combined with 40% IMS1313 achieved optimal immune responses. Compared to intramuscular injection, intradermal injection using this formulation induced 1.3-fold higher neutralizing antibody titers, demonstrating higher efficacy. CONCLUSIONS AND RELEVANCE: Intradermal vaccination using a PCV2d VLP-based vaccine improves immunogenicity and cost-effectiveness, providing a promising strategy for controlling PCV2d infections in swine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.